Peter Marks

Mr Marks has served as a director of Alterity since July 2005. He is an experienced company director with significant corporate advisory and investment experience. In his roles with these various financial institutions, Mr. Marks was responsible for advising a substantial number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.

For over 13 years until the end of August 2014, Mr. Marks was a Director of investment bank Peregrine Corporate Ltd, and is currently Chairman of Newburyport Partners, a boutique corporate and capital markets advisory firm specializing in advising small to mid-cap companies.

Mr Marks is currently a non-executive Director of Electriq Global Ltd, and also currently serves as Director of Noxopharm Ltd, an ASX listed biotechnology company, and Noxopharm subsidiary, Nyrada Inc.